Back to the list
Congress: ECR25
Poster Number: C-17574
Type: Poster: EPOS Radiologist (scientific)
Authorblock: T. Dell, J. A. Luetkens, C. C. Pieper, A. Isaak, P. A. Kupczyk, D. Kütting; Bonn/DE
Disclosures:
Tatjana Dell: Nothing to disclose
Julian Alexander Luetkens: Nothing to disclose
Claus Christian Pieper: Nothing to disclose
Alexander Isaak: Nothing to disclose
Patrick Arthur Kupczyk: Nothing to disclose
Daniel Kütting: Nothing to disclose
Keywords: Liver, CT-Quantitative, Screening, Cirrhosis
Purpose Steatosis has become a critical health problem, creating a growing need for screening1. MAFLD affects approximately 40% of the global population, with higher prevalence rates observed in Europe. As a result, non-invasive assessment of fatty liver disease is increasingly important. This study evaluates the accuracy of photon-counting CT (PCCT)-based fat quantification in contrast-enhanced scans for liver steatosis, validated against histopathology, CAP-transient elastography, and MRI proton density fat fraction (PDFF) 2,3.
Read more Methods and materials A single-center, prospective study included 178 participants with known or suspected liver disease. PCCT was performed using a dual-source system, and hepatic fat fraction was quantified via dedicated post-processing software. All examinations were acquired at 120 kVp in a portal venous phase. Comparative data were obtained using biopsy, CAP, or MRI PDFF (3T clinical system), with assessments stratified by steatosis grades. Patients included in the study had received one of the following comparative modalities for estimation of hepatic fat fraction...
Read more Results Results are summarized in table 1 Excellent agreement between PCCT and MRI PDFF measurements (ICC: 0.907, 95% CI: 0.865-0.935). Moderate correlation of PCCT-based steatosis grades with biopsy (r=0.65) and CAP (r=0.45). Bland-Altman Plot for fat fractions measured with PCCT and MRI (95% CI: 8.401 to 5.237, mean bias: 0.808)(Figure 2) PCCT threshold of 4.75% achieved 81% sensitivity and 71% specificity for detecting steatosis.
Read more Conclusion Photon-counting CT (PCCT) allows for accurate estimation of fat fraction in a standard clinical setting, suggesting applications in screening, monitoring, and disease prevention. Further investigation is needed to identify and validate high-sensitivity thresholds, particularly in diverse populations. Prospective multicenter studies are essential to validate PCCT technology as a biomarker for steatosis and establish optimal thresholds for clinical utility and clinical trials.
Read more References Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013 Oct;59(4):859-71. doi: 10.1016/j.jhep.2013.05.044. Tang A, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. 2013;267(2):422-431. Yokoo T, et al. Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. 2018;286(2):486-498.
Read more
GALLERY